- Newly approved F8 formulation of tesamorelin (EGRIFTA WR) for the reduction of excess visceral abdominal fat in adult patients with human immunodeficiency virus and lipodystrophy.
- Contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, and hypersensitivity to tesamorelin or its components.
- Common adverse events reported, such as arthralgia, injection-site reactions, pain in extremity, peripheral edema, and myalgia.
- Clinicians advised to evaluate the risk-benefit profile in patients who don't demonstrate a reduction in visceral adipose tissue.
- Each vial contains 11.6 mg of tesamorelin, yielding seven doses per vial.
Source: Therathechnologies
